Skip to main content

Table 1 Demographics and biomarker values for the diagnostic groupsa

From: CSF total tau/α-synuclein ratio improved the diagnostic performance for Alzheimer’s disease as an indicator of tau phosphorylation

  EOAD LOAD MCI SCD PD HC P
N 71 34 11 17 45 32  
Sex (M/F) 25/46 17/17 6/5 4/13 18/27 12/20 .412b
Agec 58.0 (54.0–62.0) 77.0 (73.0–80.0) 68.0 (59.0–75.0) 67.0 (61.0–73.0) 68.0 (60.0–74.5) 66.5 (62.0–68.0) .000d
MMSEe 16.0 (13.0–20.0) 19.0 (16.0–21.0) 25.0 (24.0–26.0) 29.0 (25.5–29.0) 28.0 (27.0–30.0) .000d
CDR 0/0.5/1/2/3e 0/20/33/15/3 0/13/15/6/0 0/10/1/0/0 2/15/0/0/0 15/17/0/0/0 .000f
CSF Aβ42 (pg/mL) 326.8 (258.6–488.2) 401.3 (239.6–587.3) 737.5 (445.9–806.9) 990.3 (904.3–1043.5) 774.4 (595.2–967.2) 1078.0 (982.4–1297.3) .000d
CSF T-tau (pg/mL) 534.3 (386.2–732.9) 442.6 (326.3–598.2) 283.6 (203.7–490.8) 321.9 (252.1–335.9) 159.4 (116.9–215.8) 203.3 (147.1–295.9) .000d
CSF P-tau181 (pg/mL) 77.2 (53.9–106.0) 69.9 (44.1–89.7) 54.6 (40.1–83.3) 51.5 (41.1–60.4) 34.8 (25.5–43.6) 40.3 (32.1–54.6) .000d
CSF α-syn (pg/mL) 754.2 (526.7–1163.9) 834.8 (586.5–1330.3) 889.5 (628.7–1079.5) 880.4 (689.5–1154.8) 590.9 (420.0–842.3) 669.8 (506.8–973.3) .007d
Amyloid-PET (+/−)g 50/1 18/10 1/4 1/12 1/21 .000b
  1. Abbreviations: EOAD early-onset Alzheimer’s disease, LOAD late-onset Alzheimer’s disease, MCI mild cognitive impairment, SCD subjective cognitive decline, PD Parkinson’s disease, HC healthy control, M male, F female, MMSE Mini-Mental State Examination, CDR Clinical Dementia Rating, CSF cerebrospinal fluid, 42 amyloid-β 1-42; T-tau total tau; P-tau181 phosphorylated tau 181, α-syn α-synuclein, FBB-PET18F-florbetaben positron emission tomography
  2. aData are shown as median (interquartile) unless otherwise indicated
  3. bChi-square test
  4. cExcluding EOAD and LOAD, the P value is 0.425
  5. dKruskal-Wallis test
  6. ePD was not performed the cognitive assessment
  7. fFisher’s exact test
  8. gA limited number of individuals were available for amyloid-PET scan
\